ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
17 hedge funds and large institutions have $56.6M invested in ESSA Pharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
1.34% more ownership
Funds ownership: 67.1% → 68.44% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less funds holding
Funds holding: 21 → 17 (-4)
26% less capital invested
Capital invested by funds: $76.1M → $56.6M (-$19.5M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.24M |
| 2 |
Janus Henderson Group
London,
|
+$1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.59K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$156 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.11M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$205K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$155K |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$101K |
| 5 |
Renaissance Technologies
New York
|
-$70K |
EPIX Hedge Fund Activity: Q1 2020 in Review
17 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2020, worth a combined $56.6M — down 26% from $76.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EPIX and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Soleus Capital Management, adding an estimated $2.24M. The largest seller was BVF Inc, cutting an estimated $1.11M.
- 17 institutional investors held ESSA Pharma (EPIX) as of Q1 2020, down from 21 in Q4 2019.
- Funds reported $56.6M of ESSA Pharma stock for Q1 2020, down 26% quarter-over-quarter.
- 3 funds opened new ESSA Pharma positions in Q1 2020 and 5 closed out, a net change of -2 holders.
- The largest ESSA Pharma buyer in Q1 2020 was Soleus Capital Management, an estimated $2.24M added.
- The largest ESSA Pharma seller in Q1 2020 was BVF Inc, an estimated $1.11M sold.
Based on aggregated 13F filings for Q1 2020.